Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.795
+0.075 (1.59%)
At close: Mar 20, 2026, 4:00 PM EDT
5.05
+0.26 (5.32%)
After-hours: Mar 20, 2026, 4:27 PM EDT

Radiopharm Theranostics Ratios and Metrics

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22
5737---
Market Cap Growth
19.19%----
Enterprise Value
33.638.96000
Last Close Price
4.804.64---
PS Ratio
5.2210.07---
PB Ratio
1.700.82---
P/TBV Ratio
0.910.72---
P/FCF Ratio
--1.00---
P/OCF Ratio
--1.00---
EV/Sales Ratio
3.102.47---
EV/EBITDA Ratio
--0.23---
EV/EBIT Ratio
--0.23---
EV/FCF Ratio
--0.24---
Debt / Equity Ratio
0.060.080.230.17-
Debt / EBITDA Ratio
-0.06-0.09-0.13-0.23-
Debt / FCF Ratio
-0.04-0.09-0.28-0.34-
Net Debt / Equity Ratio
-0.61-0.57-0.44-0.09-
Net Debt / EBITDA Ratio
0.680.670.260.11-
Net Debt / FCF Ratio
0.430.700.530.17-
Asset Turnover
0.040.050.000.01-
Quick Ratio
3.002.651.111.22-
Current Ratio
3.012.671.301.23-
Return on Equity (ROE)
-147.51%-109.20%-131.49%-151.87%-
Return on Assets (ROA)
-50.99%-48.29%-64.37%-92.13%-
Return on Invested Capital (ROIC)
-99.99%-85.27%-94.57%-119.38%-
Return on Capital Employed (ROCE)
-60.16%-60.59%-81.27%-111.75%-
Earnings Yield
-54.85%0.00%---
FCF Yield
-46.12%-100.18%---
Buyback Yield / Dilution
-46.91%-147.57%---
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q